Applications of bile acids as biomaterials-based modulators, in biomedical science and microfluidics
Chronic disorders such as diabetes mellitus are associated with multiple organ dysfunction, including retinopathy, neuropathy, nephropathy, peripheral vascular disease, and vascular disease. Lifelong subcutaneous insulin injections are currently the only treatment option for patients with Type 1 diabetes mellitus, and it poses numerous challenges. Since the breakthrough achieved from the Edmonton protocol in the year 2000, there has been important research to investigate whether islet cell transplantation can achieve long-term normoglycemia in patients without the need for insulin. The use of biopolymeric scaffold to enclose islet cells has also been explored to improve survivability and viability of islet cells. This review paper summarizes the latest research in using biopolymeric scaffolds in islet transplantation and how microfluidic devices can assist.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Therapeutic delivery - 13(2022), 12 vom: 01. Dez., Seite 591-604 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Koh, Wee Ling [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Artificial organs |
|---|
| Anmerkungen: |
Date Completed 07.03.2023 Date Revised 08.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/tde-2022-0044 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353672785 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353672785 | ||
| 003 | DE-627 | ||
| 005 | 20231226060539.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/tde-2022-0044 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1178.xml |
| 035 | |a (DE-627)NLM353672785 | ||
| 035 | |a (NLM)36861306 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Koh, Wee Ling |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Applications of bile acids as biomaterials-based modulators, in biomedical science and microfluidics |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.03.2023 | ||
| 500 | |a Date Revised 08.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Chronic disorders such as diabetes mellitus are associated with multiple organ dysfunction, including retinopathy, neuropathy, nephropathy, peripheral vascular disease, and vascular disease. Lifelong subcutaneous insulin injections are currently the only treatment option for patients with Type 1 diabetes mellitus, and it poses numerous challenges. Since the breakthrough achieved from the Edmonton protocol in the year 2000, there has been important research to investigate whether islet cell transplantation can achieve long-term normoglycemia in patients without the need for insulin. The use of biopolymeric scaffold to enclose islet cells has also been explored to improve survivability and viability of islet cells. This review paper summarizes the latest research in using biopolymeric scaffolds in islet transplantation and how microfluidic devices can assist | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a artificial organs | |
| 650 | 4 | |a bile acids | |
| 650 | 4 | |a bioengineering | |
| 650 | 4 | |a biomaterials | |
| 650 | 4 | |a diabetes mellitus | |
| 650 | 4 | |a transplantation | |
| 650 | 7 | |a Bile Acids and Salts |2 NLM | |
| 650 | 7 | |a Insulin |2 NLM | |
| 650 | 7 | |a Biocompatible Materials |2 NLM | |
| 700 | 1 | |a Foster, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Mooranian, Armin |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Salami, Hani |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic delivery |d 2010 |g 13(2022), 12 vom: 01. Dez., Seite 591-604 |w (DE-627)NLM203937082 |x 2041-6008 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g number:12 |g day:01 |g month:12 |g pages:591-604 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/tde-2022-0044 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |e 12 |b 01 |c 12 |h 591-604 | ||